Trial Profile
Effect of Mepolizumab on the Decrease of Systemic Corticosteroids in Patients with Severe Eosinophilic Asthma Observational Study, Cohort Follow-up Via a Nominal ATU
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 08 Mar 2018 New trial record